Analyst Ratings For Agios Pharmaceuticals (NASDAQ:AGIO)
Today, Royal Bank of Canada raised its price target on Agios Pharmaceuticals (NASDAQ:AGIO) to per share.
Some recent analyst ratings include
- 12/5/2017-Cann Reiterated Rating of Buy.
- 9/18/2017-JPMorgan Chase & Co. Reiterated Rating of Buy.
Recent Insider Trading Activity For Agios Pharmaceuticals (NASDAQ:AGIO)
Agios Pharmaceuticals (NASDAQ:AGIO) has insider ownership of 5.43% and institutional ownership of 94.32%.
- On 1/16/2018 David P Schenkein, CEO, sold 53,000 with an average share price of $73.16 per share and the total transaction amounting to $3,877,480.00.
- On 1/10/2018 Scott Biller, Insider, sold 3,000 with an average share price of $65.00 per share and the total transaction amounting to $195,000.00.
- On 12/7/2017 Lewis Clayton Jr. Cantley, Director, sold 3,838 with an average share price of $59.37 per share and the total transaction amounting to $227,862.06.
- On 12/1/2017 David P Schenkein, CEO, sold 6,000 with an average share price of $61.55 per share and the total transaction amounting to $369,300.00.
- On 12/1/2017 Scott Biller, Insider, sold 2,146 with an average share price of $60.79 per share and the total transaction amounting to $130,455.34.
- On 11/14/2017 Lewis Clayton Jr. Cantley, Director, sold 4,000 with an average share price of $60.88 per share and the total transaction amounting to $243,520.00.
- On 11/1/2017 David P Schenkein, CEO, sold 6,000 with an average share price of $63.85 per share and the total transaction amounting to $383,100.00.
Recent Trading Activity for Agios Pharmaceuticals (NASDAQ:AGIO)
Shares of Agios Pharmaceuticals closed the previous trading session at with 68.83000183105469 shares trading hands.